Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06070350 · ClinicalTrials.gov registry record · Phase 3
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
A Phase 3 study of Trauma Injury and Hemorrhagic Shock, sponsored by Philip Spinella.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT06070350 is a Phase 3 study of Trauma Injury and Hemorrhagic Shock that is actively recruiting participants, run by Philip Spinella. The registered enrollment target is 1,000 participants, above the 434-participant average among 15 other Trauma Injury trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT06070350, a Phase 3 study of Trauma Injury and Hemorrhagic Shock, is actively recruiting participants, sponsored by Philip Spinella.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid (TXA)
- BIOLOGICAL Low Titer Group O Whole Blood (LTOWB)
- BIOLOGICAL Component Therapy (CT)
Study Locations (20)
Texas
- The University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
- Children's Memorial Hermann Hospital - Houston
- University of Texas Health Science Center at San Antonio - San Antonio
Georgia
- Emory University-Arthur M. Blank Hospital - Atlanta
- Emory University-Scottish Rite Hospital - Atlanta
Tennessee
- LeBonheur Children's Hospital - Memphis
- Vanderbilt University Medical Center - Nashville
Arizona
- University of Arizona - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- University of California Davis - Sacramento
District of Columbia
- Children's National Hospital - Washington D.C.
Louisiana
- Tulane School of Medicine - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06070350
The ClinicalTrials.gov registry entry for NCT06070350 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 434-participant average among 15 other Trauma Injury trials with a reported enrollment target (130% higher). The listed sponsor is Philip Spinella, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Trauma Injury appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06070350 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06070350 about?
NCT06070350 is a clinical study titled "Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children". The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared ...
What is the current status of trial NCT06070350?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2024-11-01. Estimated completion is 2028-10-01.
What conditions does trial NCT06070350 study?
This clinical trial studies the following conditions: Trauma Injury, Hemorrhagic Shock.
What interventions are being tested in trial NCT06070350?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (TXA) (DRUG), Low Titer Group O Whole Blood (LTOWB) (BIOLOGICAL), Component Therapy (CT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06070350?
This trial is sponsored by Philip Spinella, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06070350 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
COMPLETED · Phase 3
-
Pathological Myeloid Activation After Sepsis and Trauma
RECRUITING
-
Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries
RECRUITING · NA
-
Antibiotic Use in Facial Fracture Post Injury
RECRUITING
-
Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury
RECRUITING · NA
-
The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.